Robert A. Hegele
A5035358062- Lipoproteins and Cardiovascular Health
- Lipid metabolism and disorders
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Cancer, Lipids, and Metabolism
- Genetic Associations and Epidemiology
- Nuclear Structure and Function
- Peroxisome Proliferator-Activated Receptors
- Cholesterol and Lipid Metabolism
- Diabetes and associated disorders
- Liver Disease Diagnosis and Treatment
- RNA Research and Splicing
- Genomics and Rare Diseases
- Metabolism, Diabetes, and Cancer
- Pancreatic function and diabetes
- Health Systems, Economic Evaluations, Quality of Life
- Metabolism and Genetic Disorders
- Atherosclerosis and Cardiovascular Diseases
- Pancreatitis Pathology and Treatment
- Genetic factors in colorectal cancer
- Pharmaceutical Economics and Policy
- Adipose Tissue and Metabolism
- Caveolin-1 and cellular processes
- RNA modifications and cancer
- Diet, Metabolism, and Disease
- Hormonal Regulation and Hypertension
Western University
2016-2025
Robarts Clinical Trials
2016-2025
Royal Perth Hospital
2000-2024
Icahn School of Medicine at Mount Sinai
2024
Monash University
2024
Sorbonne Université
2024
Inserm
2024
Arrowhead Pharmaceuticals (United States)
2024
New York University
2024
National Institute for Health Research
2024
The first aim was to critically evaluate the extent which familial hypercholesterolaemia (FH) is underdiagnosed and undertreated. second provide guidance for screening treatment of FH, in order prevent coronary heart disease (CHD).Of theoretical estimated prevalence 1/500 heterozygous <1% are diagnosed most countries. Recently, direct a Northern European general population approximately 1/200 with FH. All reported studies document failure achieve recommended LDL cholesterol targets large...
Abstract
Homozygous familial hypercholesterolaemia (HoFH) is a rare life-threatening condition characterized by markedly elevated circulating levels of low-density lipoprotein cholesterol (LDL-C) and accelerated, premature atherosclerotic cardiovascular disease (ACVD). Given recent insights into the heterogeneity genetic defects clinical phenotype HoFH, availability new therapeutic options, this Consensus Panel on Familial Hypercholesterolaemia European Atherosclerosis Society (EAS) critically...
Patients with Dunnigan-type familial partial lipodystrophy (FPLD) are born normal fat distribution, but after puberty experience regional and progressive adipocyte degeneration, often associated profound insulin resistance diabetes. Recently, the FPLD gene was mapped to chromosome 1q21–22, which harbours LMNA encoding nuclear lamins A C. Mutations in were shown underlie autosomal dominant Emery–Dreifuss muscular dystrophy (EDMD-AD), is characterized by skeletal muscle wasting cardiac...
Recent advances in human genetics, together with a large body of epidemiologic, preclinical, and clinical trial results, provide strong support for causal association between triglycerides (TG), TG-rich lipoproteins (TRL), TRL remnants, increased risk myocardial infarction, ischaemic stroke, aortic valve stenosis. These data also indicate that their remnants may contribute significantly to residual cardiovascular patients on optimized low-density lipoprotein (LDL)-lowering therapy. This...